查詢結果分析
來源資料
相關文獻
- Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
- Revisiting Squamous Cell Carcinoma of the Lungs--A Disease Given Less Attention
- 非小細胞肺癌在同步化學及放射線治療後之腫瘤的組織病理學變化之特徵
- Choroidal Metastasis as the Primary Presentation of Non-Small Cell Lung Cancer: A Case Report
- False Positive 18F-FDG Uptake in Mediastinal Lymph Nodes for A Patient with Pulmonary Adenocarcinoma: A Case Report
- 以側頸囊腫表徵之轉移性乳頭狀甲狀腺癌--二例報告
- Use of Cremophor EL as a MDR Reversing Agent to Enhance Intestinal Absorption of Epirubicin in Everted Gut Sacs of Rats and Human Intestinal Epithelial Caco-2 Cell Layers
- Flutamide-Induced Liver Injury: A Case Report
- Papillary and Follicular Thyroid Carcinomas with Bone Metastases: A Series of 39 Cases during a Period of 18 Years
- Morbidity with Contemporary Transrectal Biopsy of the Prostate
頁籤選單縮合
題名 | Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients=使用Erlotinib或化學治療作為野生型上皮細胞生長因素接收器之肺腺癌患者的第二線或後線之治療 |
---|---|
作者姓名(中文) | 陳育民; 羅永鴻; 吳杰鴻; 李毓芹; 彭瑞鵬; 彭汪嘉康; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 2:1 2015.03[民104.03] |
頁次 | 頁3-11 |
分類號 | 415.468 |
關鍵詞 | 腺癌; 非小細胞肺癌; Adenocarcinoma; Docetaxel; Erlotinib; Non-small-cell lung cancer; Pemetrexed; |
語文 | 英文(English) |
中文摘要 | 本研究之目的是探討野生型上皮細胞生長因素接收器之肺腺癌患者於第一線化學治 療失敗之後,使用 erlotinib,pemetrexed,或 docetaxel的治療效果差異。我們於民國 98年 7月至 101年 6月期間收集了 41個患者作分析所有人於病程中皆有使用到 erlotinib, 35人有使用pemetrexed, 30人, 有使用docetaxel。其中er,lotinib較常使用於第二線的治療 (27人,65.9%),pemetrexed較常用於第三線治療 (21人,60%),docetaxel常常用於第四線的治療 (14人,46.7%)(當比較不同的治療藥物時,p值皆小於 0.01)。這三種藥物的腫瘤反應率並無顯著之差異 (erlotinib (19.5%),pemetrexed (17.1%),docetaxel (6.7%), p=0.301)。這些藥物使用在第二線或更後線治療的無疾病進展存活時間中位數有顯著之差異(erlotinib (10.9週),pemetrexed (13.3週),docetaxel (8.3週),p=0.0261)。這些藥物使用於較前線或較後線之挽救性治療的無疾病進展存活時間並無顯著之差異。所以野生型上皮細胞生長因素接收器之肺腺癌患者於第一線化學治療失敗之後,不論使用 erlotinib, pemetrexed,或 docetaxel,皆為有效之挽救性治療。 |
英文摘要 | Background: The intent of this study was to explore the treatment efficacy of erlotinib, pemetrexed or docetaxel in individual patients with tumor EGFR wild-type pulmonary adenocarcinoma who failed previous chemotherapy. Methods: We retrospectively reviewed the clinical data of our EGFR wild-type pulmonary adenocarcinoma patients who had disease progression after first-line chemotherapy and also had received erlotinib and pemetrexed or docetaxel treatment in our institution any time from July 2009 to June 2012. Results: Forty-one patients were identified and enrolled into the present study; all of them received erlotinib treatment. Thirty-five patients received additional pemetrexed treatment and 30 patients received additional docetaxel treatment, either preceding or following failure of erlotinib treatment. Erlotinib was used more frequently as a second-line treatment in 27 of 41 (65.9%) patients, followed by pemetrexed, which was used more frequently in the third-line setting for 21 of 35 (60%) patients. Docetaxel was typically used as the fourth-line treatment for 14 of 30 (46.7%) patients (all p < 0.01 when comparing different treatment agents). There was no difference in the tumor response rate between erlotinib (19.5%), pemetrexed (17.1%), and docetaxel (6.7%) (p = 0.301). For all patients, the median progression-free survival (PFS) was 10.9 weeks, 13.3 weeks, and 8.3 weeks when using erlotinib, pemetrexed, and docetaxel, respectively, as ≥ second-line treatment (p = 0.0261). No significant difference in PFS was found for individual agents when used in an earlier or later line of salvage therapy. Conclusions: This retrospective study of tumor EGFR wild-type pulmonary adenocarcinoma patients showed that erlotinib, pemetrexed, or docetaxel, individually, provided effective salvage therapy when patients had disease progression subsequent to first-line chemotherapy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。